Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC analgesic alcohol warning health risk communication to be assessed in FDA study.

This article was originally published in The Tan Sheet

Executive Summary

OTC ANALGESIC ALCOHOL WARNING HEALTH RISK COMMUNICATION will be assessed in FDA's upcoming consumer survey of OTC drug labeling. The agency says in an Aug. 6 description of the proposed research that its purpose will be "to investigate how various methods of phrasing information in the alcohol warning influences consumers' perception of the product's risk." The study will assess the adequacy of the currently used labeling statement: "Alcohol Warning: If you generally consume three or more alcohol-containing drinks per day, you should consult your physician for advice on when and how you should take [this product] and other pain relievers."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel